Posted by Michael Wonder on 29 Sep 2025
ICER to assess vaccines for COVID-19
29 September 2025 - Report will be subject of New England CEPAC meeting in June 2026.
The ICER announced today that it will assess the comparative clinical effectiveness and value of Comirnaty (Pfizer, BioNTech), Spikevax (Moderna), mNexspike (Moderna), and Nuvaxovid (Novavax) for the prevention of COVID-19, including both the short- and long-term effects of the infection.
